A Study of SHR-2173 in Participants With Primary IgA Nephropathy

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Primary IgA Nephropathy

In brief

This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with Primary IgA Nephropathy(IgAN). The study consists of a screening period, a run-in period, a 48-week double-blind treatment period, and a 12-week follow-up period. Approximately 84 IgAN patients will be included.

Key facts

Study ID: NCT07354932
Run by: Guangdong Hengrui Pharmaceutical Co., Ltd
People needed: 84
Starts: 2026-03-09
Expected to finish: 2027-12-01
Last updated by the study team: 2026-05-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male and female participants aged 18 or older
Body weight ≥35 kg, BMI<37.5 kg/m2
At screening, 24-hour urinary protein quantification ≥1 g/ day, or 24-hour UPCR≥0.7 g/g
eGFR≥30 mL/ minute /1.73 m2 at screening
Female subjects with fertility or male participants whose partners are women of childbearing age must avoid donating sperm/eggs from the date of signing the ICF until 12 weeks after the last study medication, and agree to take contraceptive measures as specified in the protocol

You may not qualify if…

1、Presence of any of the following medical histories or comorbidities:
Renal pathology consistent with IgAN, but secondary factors could not be excluded by investigator evaluation, including but not limited to: secondary to systemic diseases, infections, autoimmune diseases or tumors;
A history of organ transplantation;
A history of splenectomy;
Presence or history of malignancy within 5 years before screening (note: skin squamous cell carcinoma, basal cell carcinoma or cervical carcinoma in situ with complete resection and no evidence of recurrence are excluded);
A history of anaphylaxis such as generalized urticaria, angioedema, or anaphylaxis, or a known history of allergy to the study drug or any component of the study drug
2、Use of any of the following drugs/treatments or participation in a clinical study:
Received systemic glucocorticoid therapy (including gut-targeted budesonide, etc.) within 12 weeks before randomization (Note: except those not used within 4 weeks before randomization and received prednisone ≤0.5mg/kg or equivalent glucocorticoid for non-IgAN disease within 52 weeks before randomization, with no more than 3 courses (each course ≤2 weeks);
Receivied immunosuppressive therapy within 12 weeks before randomization;
Received any investigational drug within 4 weeks before randomization or within the 5 half-lives of the trial drug, whichever was longer;
Received a live / attenuated live vaccine administered within 4 weeks before randomization
3、History and examination related to infection:
A history of infection (viral, bacterial, fungal, parasitic infection) within 3 months prior to screening, resulting in hospitalization and/or parenteral systemic antimicrobial therapy; Or a history of infection requiring systemic antimicrobial therapy within 14 days before randomization;
Tuberculosis (TB) or occult TB infection (one of the following conditions) :
Presence of active TB or clinical symptoms of active TB at screening;
Signs of active TB on imaging examination within 3 months before screening
4、 General situation:
Pregnant or lactating women; 2) Investigators determine that there are circumstances that affect the safety and efficacy evaluation of the investigational drug, or other circumstances not appropriate for participation in this study.

Where it is running

The First Affiliated Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China (enrolling)
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.